{"id":"cyd-dengue-vaccine-serotypes-1-2-3-and-4","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Injection site pain"},{"rate":"10-20%","effect":"Headache"},{"rate":"10-20%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL481241","moleculeType":"Small molecule","molecularWeight":"471.60"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"This vaccine works by presenting the immune system with antigens from all four dengue serotypes, stimulating the production of neutralizing antibodies and memory B cells, which can provide protection against future infections by any of the serotypes.","oneSentence":"The CYD Dengue Vaccine Serotypes 1, 2, 3, and 4 is a tetravalent dengue vaccine that targets the envelope proteins of all four dengue virus serotypes to induce a protective immune response.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:09:31.349Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of dengue fever caused by dengue virus serotypes 1, 2, 3, and 4"}]},"trialDetails":[{"nctId":"NCT00875524","phase":"PHASE2","title":"Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-03","conditions":"Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":180},{"nctId":"NCT01550289","phase":"PHASE2","title":"Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2012-03","conditions":"Dengue, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":189},{"nctId":"NCT00788151","phase":"PHASE2","title":"Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-09-26","conditions":"Dengue Virus, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":300},{"nctId":"NCT01436396","phase":"PHASE3","title":"Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-09-07","conditions":"Dengue, Dengue Hemorrhagic Fever, Yellow Fever","enrollment":792},{"nctId":"NCT01411241","phase":"PHASE3","title":"Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-07-18","conditions":"Dengue, Dengue Hemorrhagic Fever","enrollment":720},{"nctId":"NCT01254422","phase":"PHASE3","title":"Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-12-02","conditions":"Dengue Fever, Dengue Hemorrhagic Fever","enrollment":250},{"nctId":"NCT01488890","phase":"PHASE2","title":"Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-12-06","conditions":"Dengue, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":390},{"nctId":"NCT01187433","phase":"PHASE2","title":"Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-08","conditions":"Dengue, Dengue Hemorrhagic Fever","enrollment":150},{"nctId":"NCT01374516","phase":"PHASE3","title":"Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-06-08","conditions":"Dengue Fever, Dengue Hemorrhagic Fever, Dengue","enrollment":20869},{"nctId":"NCT01373281","phase":"PHASE3","title":"Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-06-03","conditions":"Dengue, Dengue Fever, Dengue Hemorrhagic Fever","enrollment":10275},{"nctId":"NCT01134263","phase":"PHASE3","title":"Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-10-05","conditions":"Dengue Fever, Dengue Hemorrhagic Fever","enrollment":715},{"nctId":"NCT01064141","phase":"PHASE2","title":"A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-01","conditions":"Dengue Fever, Dengue Hemorrhagic Fever","enrollment":210}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ChimeriVax™"],"phase":"phase_2","status":"active","brandName":"CYD Dengue Vaccine Serotypes 1, 2, 3, and 4","genericName":"CYD Dengue Vaccine Serotypes 1, 2, 3, and 4","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"The CYD Dengue Vaccine Serotypes 1, 2, 3, and 4 is a tetravalent dengue vaccine that targets the envelope proteins of all four dengue virus serotypes to induce a protective immune response. Used for Prevention of dengue fever caused by dengue virus serotypes 1, 2, 3, and 4.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}